Quick Answer
UroGen Pharma Ltd. reported Research And Development Expense of $67.11 million for the year ending 2025.
- UroGen Pharma Ltd. showed an increase of +17.4% in Research And Development Expense from 2024 to 2025.
- This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), UroGen Pharma Ltd.'s Research And Development Expense has grown by 258.9%.
- Historical annual values: Fiscal year 2025: $67.11 million | Fiscal year 2024: $57.15 million | Fiscal year 2023: $45.61 million | Fiscal year 2022: $52.91 million | Fiscal year 2021: $47.64 million | Fiscal year 2020: $47.31 million | Fiscal year 2019: $49.30 million | Fiscal year 2018: $36.93 million | Fiscal year 2017: $18.70 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: